SCHEMBL23218052

SCHEMBL23218052

CCCc1oc2ccc(-c3cccc(CN)c3)cc2c1COc1cc(C)ccc1CC(=O)OCC

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CFD P00746 8/20 0.42
PLAU P00749 7/20 0.40
PLG P00747 6/20 0.40
F11 P03951 1/20 0.40
KLKB1 P03952 1/20 0.40
F7 P08709 1/20 0.40
TPSB2 P20231 1/20 0.40
ANO1 Q5XXA6 1/20 0.36
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36
RXRG P48443 1/20 0.36
ACLY P53396 1/20 0.36
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
POLB P06746 1/20 0.35
KMT2A Q03164 1/20 0.35
PLAT P00750 3/20 0.35
HSD11B1 P28845 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852928 1.00 CFD (0.42) CFDPLAUPLGF11KLKB1
SCHEMBL23218560 0.94 CFD (0.43) CFDPLAUPLGF11KLKB1
SCHEMBL29852663 0.94 CFD (0.43) CFDPLAUPLGF11KLKB1
SCHEMBL29591303 0.92 CFD (0.49) CFDPLAUPLGF11KLKB1
SCHEMBL23218579 0.92 CFD (0.49) CFDPLAUPLGF11KLKB1
SCHEMBL29852619 0.92 CFD (0.51) CFDPLAUPLGF11KLKB1
SCHEMBL23219099 0.92 CFD (0.51) CFDPLAUPLGF11KLKB1
SCHEMBL23218191 0.92 CFD (0.41) CFDPLAUPLGF11KLKB1
SCHEMBL29852970 0.92 CFD (0.41) CFDPLAUPLGF11KLKB1
SCHEMBL23218387 0.90 CFD (0.45) CFDPLAUPLGF11KLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885PLAU 1119/4885PLG 421/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885PLAU 144/4885PLG 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.